Zacks Investment Research Downgrades USANA Health Sciences (NYSE:USNA) to Sell

USANA Health Sciences (NYSE:USNAGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Saturday, Zacks.com reports.

According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “

Several other research firms have also issued reports on USNA. TheStreet lowered shares of USANA Health Sciences from a “b” rating to a “c+” rating in a report on Wednesday, February 9th. DA Davidson dropped their target price on shares of USANA Health Sciences from $86.00 to $76.00 in a report on Wednesday. Finally, StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, USANA Health Sciences presently has an average rating of “Hold” and an average target price of $105.00.

NYSE USNA opened at $76.66 on Friday. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 14.17 and a beta of 0.87. USANA Health Sciences has a twelve month low of $71.19 and a twelve month high of $107.85. The stock has a fifty day simple moving average of $81.62 and a 200 day simple moving average of $92.71.

USANA Health Sciences (NYSE:USNAGet Rating) last released its quarterly earnings results on Tuesday, April 26th. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. USANA Health Sciences had a return on equity of 27.04% and a net margin of 9.41%. During the same period last year, the firm posted $1.45 EPS. Sell-side analysts anticipate that USANA Health Sciences will post 5.28 earnings per share for the current year.

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 312 shares of the firm’s stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $89.62, for a total value of $27,961.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Walter Noot sold 1,153 shares of the company’s stock in a transaction that occurred on Monday, February 14th. The stock was sold at an average price of $92.02, for a total value of $106,099.06. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,653 shares of company stock worth $600,825. 0.36% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of USNA. Reilly Financial Advisors LLC purchased a new stake in USANA Health Sciences in the 4th quarter valued at $32,000. Point72 Hong Kong Ltd raised its holdings in shares of USANA Health Sciences by 488.0% in the third quarter. Point72 Hong Kong Ltd now owns 488 shares of the company’s stock valued at $45,000 after purchasing an additional 405 shares during the last quarter. Altshuler Shaham Ltd lifted its position in shares of USANA Health Sciences by 28.3% during the third quarter. Altshuler Shaham Ltd now owns 508 shares of the company’s stock valued at $47,000 after purchasing an additional 112 shares in the last quarter. Covestor Ltd purchased a new position in USANA Health Sciences during the fourth quarter worth about $49,000. Finally, CWM LLC bought a new stake in USANA Health Sciences in the 4th quarter worth about $71,000. Institutional investors own 54.82% of the company’s stock.

USANA Health Sciences Company Profile (Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

Read More

Get a free copy of the Zacks research report on USANA Health Sciences (USNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.